English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

This phase Ib study randomized patients with stable sickle cell disease ( SCD ) aged 18–65 years to twice‐daily  PF ‐04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. Blood samples were collected at baseline and various posttreatment time points for assessments of  PF ‐04447943 pharmacokinetics ( PK s)/pharmacodynamics ( PD s). Change from baseline in potential  SCD ‐related biomarkers was evaluated. Of 30 patients, 15 received hydroxyurea and 28 completed the study.  PF ‐04447943, with/without hydroxyurea, was generally well tolerated, with no treatment‐related serious adverse events. Plasma  PF ‐04447943 exposure was dose proportional. Twice‐daily  PF ‐04447943 25 mg significantly reduced the number and size of circulating monocyte‐platelet and neutrophil‐platelet aggregates and levels of circulating soluble E‐selectin at day 29 vs. baseline (adjusted  P  < 0.15).  PF ‐04447943 demonstrated  PK / PD  effects suggestive of inhibiting pathways that may contribute to vaso‐occlusion. This study also provides guidance regarding biomarkers for future  SCD  studies.

PF ‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study